Covax and the rise of the ‘super public private partnership’ for global health

Datos Bibliográficos

ID15541663
AutoresKaterini T Storeng (0000-0003-0032-7006, London School of Hygiene & Tropical Medicine, autor de correspondencia), Antoine de Bengy Puyvallée (0000-0002-5800-3701, University of Oslo), F Stein (0000-0002-0123-9895, University of Oslo)
Año2021
Volumen18
Número1
Páginas1987502-1987502
Fecha de publicación2021-10-22
Peer ReviewedSí
Open AccessSí
TipoARTICLE
RevistaGlobal Public Health (JOURNAL)
Identificadores de la revistaISSN: 1744-1692 • E-ISSN: 1744-1706
EditorialTaylor & Francis (PUBLISHER • GB)
DOI10.1080/17441692.2021.1987502
PMID34686103
OpenAlexW3207737652
IdiomaEN
Citas recibidas39
Referencias citadas20

COVAX, the vaccines pillar of the Access to Covid-19 Tools Accelerator (ACT-A), has been promoted as 'the only global solution' to vaccine equity and ending the Covid-19 pandemic. ACT-A and COVAX build on the public-private partnership (PPP) model that dominates global health governance, but take it to a new level, constituting an experimental form that we call the 'super-PPP'. Based on an analysis of COVAX's governance structure and its difficulties in achieving its aims, we identify several features of the super-PPP model. First, it aims to coordinate the fragmented global health field by bringing together existing PPPs in an extraordinarily complex Russian Matryoshka doll-like structure. Second, it attempts to scale up a governance model designed for donor-dependent countries to tackle a health crisis affecting the entire world, pitting it against the self-interest of its wealthiest government partners. Third, the super-PPP's structural complexity obscures the vast differences between constituent partners, giving pharmaceutical corporations substantial power and making public representation, transparency, and accountability elusive. As a super-PPP, COVAX reproduces and amplifies challenges associated with the established PPPs it incorporates. COVAX's limited success has sparked a crisis of legitimacy for the voluntary, charity-based partnership model in global health, raising questions about its future

Accountability · Business · Civil society · Corporate governance · Equity (law · General partnership · Global governance · Global health · Health care · Legitimacy · Political science · Politics · Public health · Public–private partnership · Transparency (behavior · Global Health and Surgery · Global Maternal and Child Health · Global Public Health Policies and Epidemiology · Law · Medicine · Public Administration · Finance